Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week Low – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price hit a new 52-week low on Thursday . The stock traded as low as $8.91 and last traded at $10.40, with a volume of 592113 shares changing hands. The stock had previously closed at $9.37.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on BCAX shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Stifel Nicolaus set a $48.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, HC Wainwright reduced their price objective on shares of Bicara Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Up 11.0 %

The stock’s fifty day simple moving average is $12.84 and its 200 day simple moving average is $17.03.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08). On average, equities analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in Bicara Therapeutics in the 4th quarter worth approximately $25,000. Spire Wealth Management acquired a new position in Bicara Therapeutics in the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets acquired a new position in Bicara Therapeutics in the 4th quarter worth approximately $32,000. Legal & General Group Plc acquired a new position in Bicara Therapeutics in the 4th quarter worth approximately $33,000. Finally, Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.